STOCK TITAN

CV Sciences (CVSI) DEF 14A Filings

CVSI OTC

Here are the DEF 14A proxy statements from CV Sciences Inc (CVSI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CVSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVSI filings page.

Rhea-AI Summary

CV Sciences, Inc. is asking stockholders to approve routine annual matters and a major capital-structure change at its June 2, 2026 virtual meeting. Stockholders will vote on electing three directors, authorizing a reverse stock split between 1-for-10 and 1-for-800 at the Board’s discretion through May 30, 2029, and ratifying Haskell & White LLP as auditor for 2026. The company had 193,458,420 common shares outstanding as of April 6, 2026, with a majority of voting power required for the reverse split and auditor ratification proposals. The reverse split is intended to increase the share price to support a potential Nasdaq Capital Market listing and expand the investor base, while leaving authorized share counts and par value unchanged.